Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderna mRNA Vaccines Systems Biology Study
NCT05397223Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- May 2022
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RNA-100-AR02, mRNA-1647, elasomeran and mRNA-1010 in respiratory syncytial virus infection (RSV), cytomegalovirus infection (CMV), coronavirus disease 2019 (COVID-19) and 1 more, sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Reactogenicity Adverse Reactions at 7 days, Unsolicited Adverse Events at 28 days and 2 more. Started May 2022; status: completed.
02
Drugs
RNA-100-AR02mRNA-1647elasomeranmRNA-1010
03
Conditions
respiratory syncytial virus infection (RSV)cytomegalovirus infection (CMV)coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT05397223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397223.